JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo RIUMAComunidades & ColeccionesPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosEsta colecciónPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentros

    Mi cuenta

    AccederRegistro

    Estadísticas

    Ver Estadísticas de uso

    DE INTERÉS

    Datos de investigaciónReglamento de ciencia abierta de la UMAPolítica de RIUMAPolitica de datos de investigación en RIUMASHERPA/RoMEODulcinea
    Preguntas frecuentesManual de usoDerechos de autorContacto/Sugerencias
    Ver ítem 
    •   RIUMA Principal
    • Investigación
    • Farmacología y Pediatría - (FP)
    • FP - Contribuciones a congresos científicos
    • Ver ítem
    •   RIUMA Principal
    • Investigación
    • Farmacología y Pediatría - (FP)
    • FP - Contribuciones a congresos científicos
    • Ver ítem

    Compassionate use of medicinal products: a multicenter study

    • Autor
      Blanco-Reina, EncarnacionAutoridad Universidad de Málaga; Muñoz-García, Azucena; Cárdenas Aranzana, Manuel; Morillo Verdugo, Ramón; Moreno, José Luís; [et al.]
    • Fecha
      2014-10-22
    • Palabras clave
      Medicamentos
    • Resumen
      Compassionate Use (CU) is a way of making available to patients with an unmet medical need a promising medicine wich has not been authorised for their condition. The main objective of this study was to describe the magnitude and profile of the CU in a sample of Andalusian public hospitals. As a secondary objective we wanted to analyze the evolution of these new treatment options under development. Methods: A cross-sectional study including all applications of CU in 2010. Setting: 7 hospitals, 6 different provinces. Variables: center, clinical area, medicinal product, ATC classification, therapeutic indications, and approval by the EMA or AEMPS during the four following years. Results: A total of 194 applications regarding CU of drugs were submitted to the respective Pharmacy Committees. Among them we identified 27 different types of CU. Reina Sofía Hospital (Córdoba) was the most active center, both in number of applications (24%) and variety of them (15 of the 27 types). Drugs such as dalfampridine, decitabine, defibrotide and figitumumab only were requested from this center. In all, the most frequent CU were: bendamustine for lymphoma (12% of applications) and 5-aminolevulinic acid for surgery for malignant glioma (12%), followed by treprostinil (10%), everolimus (8.2%) and idebenone (8%). The ATC L Group (antineoplastic and inmunomodulating) accounted for almost 60% of all CU. Stem cell therapy for advanced chronic lower limb ischaemia, diacetylmorphine for heroin substitution and norcholesterol (radio drug) were also included as CU. After 4 years, 60% of drugs has achieved marketing authorisation. The remaining 40% have not yet managed license or have been rejected by the EMA (eg gentuzumab and idebenone). Conclusion: CU showed a variable profile between the different hospitals. Early access to certain investigational drugs has been supported by the high percentage of marketing authorisations. However, there are uses with some uncertainty.
    • URI
      http://hdl.handle.net/10630/8289
    • Compartir
      RefworksMendeley
    Mostrar el registro completo del ítem
    Ficheros
    Compassionate Use. A multicenter study E Blanco-Reina -2.pdf (210.0Kb)
    Colecciones
    • FP - Contribuciones a congresos científicos

    Estadísticas

    Ver Estadísticas de uso
    Buscar en Dimension
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
     

     

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA